These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 2339369)

  • 21. Thrombolytic therapy in acute myocardial infarction: comparison of procoagulant effects of streptokinase and alteplase regimens with focus on the kallikrein system and plasmin.
    Hoffmeister HM; Szabo S; Kastner C; Beyer ME; Helber U; Kazmaier S; Wendel HP; Heller W; Seipel L
    Circulation; 1998 Dec; 98(23):2527-33. PubMed ID: 9843458
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Fibrinolysis and hemorrhage after streptokinase in acute myocardial infarct].
    Cassin M; Charmet PA; Rellini G; Molaro G; Bitto S; Brieda M; Zanuttini D
    G Ital Cardiol; 1987 Jul; 17(7):601-4. PubMed ID: 3678711
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Coagulation and fibrinolytic changes in evolving acute myocardial infarction treated by high-dose, brief-duration intracoronary or intravenous streptokinase.
    Lurie AA; Rogers WJ; Gross LF
    Am J Clin Pathol; 1990 Feb; 93(2):246-51. PubMed ID: 2301285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in interstitial collagen metabolism during acute myocardial infarction treated with streptokinase or tissue plasminogen activator.
    Peuhkurinen K; Risteli L; Jounela A; Risteli J
    Am Heart J; 1996 Jan; 131(1):7-13. PubMed ID: 8554022
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolytic versus fibrinogenolytic activity of rt-PA and streptokinase in patients with acute myocardial infarction.
    Prisco D; Bonechi F; Scarti L; Tramontana M; Abbate R; Gensini GF
    Angiology; 1990 Aug; 41(8):616-20. PubMed ID: 2117862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thrombin generation, inhibition and clinical outcomes in patients with acute myocardial infarction treated with thrombolytic therapy and heparin: results from the GUSTO-I Trial. GUSTO-I Hemostasis Substudy Group. Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries.
    Granger CB; Becker R; Tracy RP; Califf RM; Topol EJ; Pieper KS; Ross AM; Roth S; Lambrew C; Bovill EG
    J Am Coll Cardiol; 1998 Mar; 31(3):497-505. PubMed ID: 9502626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Platelet function during and after thrombolytic therapy for acute myocardial infarction with reteplase, alteplase, or streptokinase.
    Moser M; Nordt T; Peter K; Ruef J; Kohler B; Schmittner M; Smalling R; Kübler W; Bode C
    Circulation; 1999 Nov; 100(18):1858-64. PubMed ID: 10545429
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of fibrin degradation products during fibrinolytic therapy for acute myocardial infarction.
    Francis CW; Connaghan DG; Marder VJ
    Circulation; 1986 Nov; 74(5):1027-36. PubMed ID: 3533310
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
    Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
    J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Acute myocardial infarction: thrombolytic efficacy of 500.000 UI of streptokinase combined with heparin].
    Aninat M; Col JJ; Rankin J; Jacquet L; Anwar A; Etienne J
    Rev Med Chil; 1990 Aug; 118(8):862-7. PubMed ID: 2152229
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic thrombin generation and activity resistant to low molecular weight heparin administered prior to streptokinase in patients with acute myocardial infarction.
    Nilsen DW; Gøransson L; Larsen AI; Hetland O; Kierulf P
    Thromb Haemost; 1997 Jan; 77(1):57-61. PubMed ID: 9031450
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The incidence and mechanism of hypotension following thrombolytic therapy for acute myocardial infarction with streptokinase-containing agents--lack of relationship to pretreatment streptokinase resistance.
    Gemmill JD; Hogg KJ; Douglas JT; Dunn FG; Lowe GD; Rae AP; Hillis WS
    Eur Heart J; 1993 Jun; 14(6):819-25. PubMed ID: 8325311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant hirudin (lepirudin) for the improvement of thrombolysis with streptokinase in patients with acute myocardial infarction: results of the HIT-4 trial.
    Neuhaus KL; Molhoek GP; Zeymer U; Tebbe U; Wegscheider K; Schröder R; Camez A; Laarman GJ; Grollier GM; Lok DJ; Kuckuck H; Lazarus P
    J Am Coll Cardiol; 1999 Oct; 34(4):966-73. PubMed ID: 10520777
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Activation of complement and kinin systems after thrombolytic therapy in patients with acute myocardial infarction. A comparison between streptokinase and recombinant tissue-type plasminogen activator.
    Agostoni A; Gardinali M; Frangi D; Cafaro C; Conciato L; Sponzilli C; Salvioni A; Cugno M; Cicardi M
    Circulation; 1994 Dec; 90(6):2666-70. PubMed ID: 7994806
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thrombolytic therapy reduces red blood cell aggregation in plasma without affecting intrinsic aggregability.
    Ben-Ami R; Sheinman G; Yedgar S; Eldor A; Roth A; Berliner AS; Barshtein G
    Thromb Res; 2002 Mar; 105(6):487-92. PubMed ID: 12091047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rate of fibrinogen breakdown related to coronary patency and bleeding complications in patients with thrombolysis in acute myocardial infarction--results from the PRIMI trial.
    Ostermann H; Schmitz-Huebner U; Windeler J; Bär F; Meyer J; van de Loo J
    Eur Heart J; 1992 Sep; 13(9):1225-32. PubMed ID: 1396833
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of acute myocardial infarction and rt-PA therapy on circulating fibrinogen.
    Seifried E; Oethinger M; Tanswell P; Hoegee-de Nobel E; Nieuwenhuizen W
    Thromb Haemost; 1993 Apr; 69(4):321-7. PubMed ID: 8497843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Influence of circulating D-dimer levels on assays of fibrinogen.
    Koh SC; Chew CY; Viegas OA; Choo M; Ratnam SS
    Ann Acad Med Singap; 1994 Nov; 23(6):856-60. PubMed ID: 7741499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparisons of characteristics and outcomes among women and men with acute myocardial infarction treated with thrombolytic therapy. GUSTO-I investigators.
    Weaver WD; White HD; Wilcox RG; Aylward PE; Morris D; Guerci A; Ohman EM; Barbash GI; Betriu A; Sadowski Z; Topol EJ; Califf RM
    JAMA; 1996 Mar; 275(10):777-82. PubMed ID: 8598594
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.